The DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma
Open accessPublished version of a preprint
Abstract
Malignant mesotheliomas are highly aggressive tumors usually caused by exposure to asbestos. Germline-inactivating mutations of BAP1 predispose to mesothelioma and certain other cancers. However, why mesothelioma is the predominate malignancy in some BAP1 families and not others, and whether exposure to asbestos is required for development of mesothelioma in BAP1 mutation carriers are not known. To address these questions experimentally, we generated a Bap1(+/-) knockout mouse model to assess its susceptibility to mesothelioma upon chronic exposure to asbestos. Bap1(+/-) mice exhibited a significantly higher incidence of asbestos-induced mesothelioma than wild-type (WT) littermates (73% vs. 32%, respectively). Furthermore, mesotheliomas arose at an accelerated rate in Bap1(+/-) mice than in WT animals (median survival, 43 weeks vs. 55 weeks after initial exposure, respectively) and showed increased invasiveness and proliferation. No spontaneous mesotheliomas were seen in unexposed Bap1(+/-) mice followed for up to 87 weeks of age. Mesothelioma cells from Bap1(+/-) mice showed biallelic inactivation of Bap1, consistent with its proposed role as a recessive cancer susceptibility gene. Unlike in WT mice, mesotheliomas from Bap1(+/-) mice did not require homozygous loss of Cdkn2a. However, normal mesothelial cells and mesothelioma cells from Bap1(+/-) mice showed downregulation of Rb through a p16(Ink4a)-independent mechanism, suggesting that predisposition of Bap1(+/-) mice to mesothelioma may be facilitated, in part, by cooperation between Bap1 and Rb. Drawing parallels to human disease, these unbiased genetic findings indicate that BAP1 mutation carriers are predisposed to the tumorigenic effects of asbestos and suggest that high penetrance of mesothelioma requires such environmental exposure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BAP1 mutations simultaneously impair (1) transcription and gene expression, (2) the mechanisms regulating cell death and DNA repair, and (3) metabolic pathways, increasing cancer risk [136,137,138] (Figure 2).”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [137]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462 · cited 13×
“Array-CGH (aCGH) with Agilent 244K genomic DNA arrays was performed on asbestosinduced MMs from Bap1 +/-and WT mice as previously described (31).”
InfluentialGermline BAP1 Mutations Predispose to Malignant Mesothelioma
Testa, J. R., Cheung, M., Pei, J., Below, J. E., Tan, Y., Sementino, E., Cox, N. J., Dogan, A. U., Pass, H. I., Trusa, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.912 · Cited by 1,076 · cited 13×
“Thus, as originally proposed, MM may only predominate when there is exposure to asbestos (11).”
InfluentialSelf-citationGermline mutations in BAP1 predispose to melanocytic tumors
Wiesner, T., Obenauf, A. C., Murali, R., Fried, I., Griewank, K. G., Ulz, P., Windpassinger, C., Wackernagel, W., Loy, S., Wolf, I., et al. (2011) · Nature Genetics · doi:10.1038/ng.910 · Cited by 725 · cited 3×
“The first reports of BAP1 families (17, 26) involved a selection bias, in the sense that the investigators were drawn to their families because of the high incidence of a particular cancer type, but subsequent work has revealed that malignant mesothelioma and atypical melanocytic neoplasms are not always the predomina…”
Jensen, D. E., Proctor, M., Marquis, S. T., Gardner, H. P., Ha, S. I., Chodosh, L. A., Ishov, A. M., Tommerup, N., Vissing, H., Sekido, Y., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201861 · Cited by 723 · cited 1×
“colleagues identified a novel protein, BRCA1-associated protein 1 (BAP1), a nuclear-localized deubiquitylase, and intragenic homozygous rearrangements and deletions of BAP1were found in several lung carcinoma cell lines (8).”
Self-citationBott, M., Brevet, M., Taylor, B. S., Shimizu, S., Ito, T., Wang, L., Creaney, J., Lake, R. A., Zakowski, M. F., Reva, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.855 · Cited by 717 · cited 1×
“53 sporadic pleural malignant mesotheliomas revealed that 6 of 12 tumors with BAP1mutations did not exhibit allelic losses ofCDKN2A; moreover, 17 of 20 tumors with homozygous losses ofCDKN2A did not showpointmutations inBAP1 (10).”
Flores, R. M., Pass, H. I., Seshan, V. E., Dycoco, J., Zakowski, M., Carbone, M., Bains, M. S., & Rusch, V. W. (2008) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2007.10.054 · Cited by 617 · cited 1×
“Malignant mesothelioma is a highly aggressive, treatmentresistant cancer (1) causally related to asbestos exposure (2–4).”
Carbone, M., Yang, H., Pass, H. I., Krausz, T., Testa, J. R., & Gaudino, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3459 · Cited by 590 · cited 2×
“The first reports of BAP1 families (17, 26) involved a selection bias, in the sense that the investigators were drawn to their families because of the high incidence of a particular cancer type, but subsequent work has revealed that malignant mesothelioma and atypical melanocytic neoplasms are not always the predomina…”
Self-citationAbdel-Rahman, M. H., Pilarski, R., Cebulla, C. M., Massengill, J. B., Christopher, B. N., Boru, G., Hovland, P., & Davidorf, F. H. (2011) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2011-100156 · Cited by 487 · cited 1×
“The first reports of BAP1 families (17, 26) involved a selection bias, in the sense that the investigators were drawn to their families because of the high incidence of a particular cancer type, but subsequent work has revealed that malignant mesothelioma and atypical melanocytic neoplasms are not always the predomina…”
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Dey, A., Seshasayee, D., Noubade, R., French, D. M., Liu, J., Chaurushiya, M. S., Kirkpatrick, D. S., Pham, V. C., Lill, J. R., Bakalarski, C. E., et al. (2012) · Science · doi:10.1126/science.1221711 · Cited by 412 · cited 3×
“Hematologic assessment of Bap1þ/ mice In several Bap1þ/ mice not exposed to asbestos, hematologic assessment was performed on bone marrow and peripheral blood to rule out the possibility of MDS, a phenotype observed in Bap1 conditional knockout mice (27), or other hematologic disease.”
InfluentialGC-Rich Sequence Elements Recruit PRC2 in Mammalian ES Cells
Mendenhall, E. M., Koche, R. P., Truong, T., Zhou, V. W., Issac, B., Chi, A. S., Ku, M., & Bernstein, B. E. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001244 · Cited by 412 · cited 1×
“In addition, BAP1 mutation and decreased BAP1 expression have been shown to be associated with increased methylation of PRC2 target genes (34), and GC-rich DNA can itself suffice to recruit PRC2 even in the absence of more complex DNA sequence motifs (35).”
Cited by
Cigognetti, M., Lonardi, S., Fisogni, S., Balzarini, P., Pellegrini, V., Tironi, A., Bercich, L., Bugatti, M., Rossi, G., Murer, B., et al. (2015) · Modern Pathology · doi:10.1038/modpathol.2015.65 · Cited by 306
Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer
Carbone, M., Harbour, J. W., Brugarolas, J., Bononi, A., Pagano, I., Dey, A., Krausz, T., Pass, H. I., Yang, H., & Gaudino, G. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1220 · Cited by 287
“BAP1’s role in increasing susceptibility to asbestos, UV light, and ionizing radiation has been established in primary human fibroblasts and mesothelial cells in culture (4), and it has been demonstrated in mice exposed to asbestos (62, 63).”
BackgroundComprehensive Study of the Clinical Phenotype of Germline BAP1 Variant-Carrying Families Worldwide
Walpole, S., Pritchard, A. L., Cebulla, C. M., Pilarski, R., Stautberg, M., Davidorf, F. H., de la Fouchardière, A., Cabaret, O., Golmard, L., Stoppa-Lyonnet, D., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy171 · Cited by 253
Self-citationMesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival
Baumann, F., Flores, E., Napolitano, A., Kanodia, S., Taioli, E., Pass, H., Yang, H., & Carbone, M. (2015) · Carcinogenesis · doi:10.1093/carcin/bgu227 · Cited by 254
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma
Panou, V., Gadiraju, M., Wolin, A., Weipert, C. M., Skarda, E., Husain, A. N., Patel, J. D., Rose, B., Zhang, S. R., Weatherly, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5204 · Cited by 229
Metadata
- Authors
- Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., Peng, H., Karar, J., Rauscher, F. J., & Testa, J. R.
- Affiliations
- Fox Chase Cancer Center (US)
- The Wistar Institute (US)
- Corresponding author
- Testa, Joseph R.
- ORCID
- Venue
- Cancer Research
- Published
- 2014-08-13
- Volume
- 74
- Issue
- 16
- Pages
- 4388-4397
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4165574
- OpenAlex
- W2050426104
- Cited by
- 144
- References
- 45
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 2 · 2023: 11 · 2022: 13 · 2021: 14 · 2020: 13 · 2019: 11 · 2018: 18 · 2017: 16 · 2016: 17 · 2015: 12 · 2014: 5
- FWCI
- 13.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Pennsylvania
- National Institutes of Health (5r01ca175691-05)
- Fox Chase Cancer Center
- National Cancer Institute (CA-175691, R01CA163761, R01-CA175691, P30CA006927, P30CA010815, CA06927)
- National Institute of Environmental Health Sciences (P30ES013508)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- BAP1, germline mutations, malignant mesothelioma, asbestos exposure, cancer susceptibility, biallelic inactivation, CDKN2A, Rb, p16INK4a, tumor invasion, tumor cell proliferation, penetrance
- MeSH terms
- Mesothelioma, Malignant, Animals, Asbestos, Disease Models, Animal, Female, Genotype, Lung Neoplasms, Mesothelioma, Germ-Line Mutation, Mice, Knockout, Genetic Predisposition to Disease, Tumor Suppressor Proteins, Ubiquitin Thiolesterase, Mice, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma. https://app.cochat.ai/papers/10.1158/0008-5472.can-14-1328
- The paper
- Xu, J., Kadariya, Y., Cheung, M., Pei, J., Talarchek, J., Sementino, E., Tan, Y., Menges, C. W., Cai, K. Q., Litwin, S., Peng, H., Karar, J., Rauscher, F. J., & Testa, J. R. (2014). Germline Mutation of Bap1 Accelerates Development of Asbestos-Induced Malignant Mesothelioma. Cancer Research. https://doi.org/10.1158/0008-5472.can-14-1328
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.